ESMO: Recommendations on the use of circulating tumour DNA assays for cancer patients
ESMO has released a report from the ESMO Precision Medicine Working Group on recommendations on…
Browsing: ESMO
ESMO: New phase III data show tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced oesophageal cancer in combination with chemotherapy
New results from the phase III RATIONALE 306 trial show that tislelizumab plus chemotherapy significantly improved…
New ESMO framework to resolve uncertainties about the de-intensification of cancer treatments
ESMO has developed a new evidence-based classification to guide research and interpretation of data on…
Ribociclib added to endocrine therapy extends survival in postmenopausal patients with metastatic breast cancer
A study led by researchers from The University of Texas MD Anderson Cancer Center in…
Breast cancer patients with an inherited BRCA1 or BRCA2 abnormality: New treatment reduces deaths by 32%
Results from a global clinical trial have shown a 32% reduction in breast cancer deaths…
ESMO 2021: First-line CDK 4/6 inhibition shows overall survival benefit for metastatic breast cancer
Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for…
ESMO 2021: COVID-19 mortality rates in people with cancer not showing same reduction as those with no history of cancer
A large prospective study of COVID-19 outcomes in people with a history of cancer has…
ESMO 2021: Artificial intelligence predicts the risk of recurrence for women with the most common breast cancer
The RACE AI study conducted by Gustave Roussy and the startup Owkin, as part of…
ESMO 2021: HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center, USA, has found…
ESMO 2021: Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer
The addition of immunotherapy to standard first-line treatment extends survival by eight months for patients…